Survivorship and Supportive Care for Gynecologic Cancer Management in the Era of Precision Medicine

Advances in precision medicine are reshaping the management of gynecologic cancers, with molecular profiling, biomarker-guided treatment selection, targeted agents, immunotherapy, antibody-drug conjugates, and maintenance strategies increasingly integrated into routine care. These developments have improved disease control and extended survival for many patients with ovarian, endometrial, cervical, vulvar, vaginal, and other rare gynecologic malignancies. At the same time, they have introduced new clinical complexities that extend well beyond tumor response alone. As treatment paradigms become more individualized, survivorship and supportive care must evolve accordingly to address the multidimensional needs of patients during and after treatment.Patients treated for gynecologic cancers frequently experience persistent and overlapping physical, psychological, sexual, reproductive, and social sequelae. Symptom burden may include fatigue, neuropathy, pain, sexual dysfunction, menopausal symptoms, infertility, bowel and bladder dysfunction, lymphedema, sleep disturbance, cognitive impairment, anxiety, depression, and financial distress. In parallel, newer systemic therapies may produce distinct acute and chronic toxicities that do not fit traditional supportive care frameworks developed around cytotoxic chemotherapy. This creates an urgent need to better characterize survivorship trajectories, identify patients at greatest risk for late effects, and develop personalized supportive care strategies that can be integrated across the cancer continuum.This Research Topic will explore how survivorship principles can be embedded into contemporary gynecologic oncology practice in ways that are evidence-based, equitable, and responsive to individual risk profiles. Particular interest lies in models of care that connect active treatment with long-term follow-up, rehabilitation, symptom management, psychosocial support, fertility and sexual health care, health behavior interventions, and primary care coordination. We also welcome work examining how digital health tools, patient-reported outcomes, remote monitoring, and risk-stratified follow-up pathways can improve longitudinal assessment and intervention delivery.By bringing together clinical, translational, behavioral, and health services perspectives, this Research Topic aims to advance a more precise approach to survivorship—one that aligns supportive care with tumor biology, treatment exposure, patient characteristics, and evolving needs over time. Ultimately, improving outcomes in gynecologic oncology requires not only extending survival, but also preserving function, quality of life, and well-being across the full trajectory of care.Topic that are particularly of interest include, but are not limited to: • Survivorship needs across ovarian, endometrial, cervical, vulvar, vaginal, and rare gynecologic cancers• Supportive care challenges associated with targeted therapies, immunotherapy, maintenance therapy, and other precision oncology approaches• Acute, chronic, and late toxicities of contemporary gynecologic cancer treatments• Patient-reported outcomes, symptom monitoring, and digital survivorship tools• Fatigue, pain, neuropathy, cognitive symptoms, sleep disturbance, and functional impairment• Sexual health, reproductive health, fertility preservation, and menopausal care• Psychosocial distress, mental health, body image, and relationship impacts• Bowel, bladder, pelvic floor, and lymphedema-related sequelae• Rehabilitation, exercise, nutrition, and lifestyle-based supportive interventions• Risk-stratified follow-up, care pathways, and survivorship care planning• Integration of supportive care into routine gynecologic oncology practice• Care coordination across oncology, primary care, rehabilitation, and allied health services• Disparities, access, and equity in survivorship and supportive care delivery• Health services, implementation, and real-world models of survivorship carePlease note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal. Topic editors: Lawrence Kasherman, Carolyn Ee, Karel Kostev Source: https://www.frontiersin.org/research-topics/78254/survivorship-and-supportive-care-for-gynecologic-cancer-management-in-the-era-of-precision-medicine